Teligent EPS - Earnings per Share 2012-2021 | TLGT
Teligent eps - earnings per share from 2012 to 2021. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Teligent Annual EPS | |
|---|---|
| 2020 | $-14.67 |
| 2019 | $-4.67 |
| 2018 | $-6.80 |
| 2017 | $-2.80 |
| 2016 | $-2.30 |
| 2015 | $-0.70 |
| 2014 | $0.90 |
| 2013 | $-0.30 |
| 2012 | $-1.00 |
| 2011 | $-0.80 |
| Teligent Quarterly EPS | |
|---|---|
| 2021-06-30 | $-0.14 |
| 2021-03-31 | $0.03 |
| 2020-12-31 | $-7.05 |
| 2020-09-30 | $-0.08 |
| 2020-06-30 | $-2.56 |
| 2020-03-31 | $-4.98 |
| 2019-12-31 | $-1.01 |
| 2019-09-30 | $-1.32 |
| 2019-06-30 | $-0.74 |
| 2019-03-31 | $-1.60 |
| 2018-12-31 | $-2.70 |
| 2018-09-30 | $-0.70 |
| 2018-06-30 | $-2.50 |
| 2018-03-31 | $-0.90 |
| 2017-12-31 | $-1.10 |
| 2017-09-30 | $-1.70 |
| 2017-06-30 | $-0.20 |
| 2017-03-31 | $0.20 |
| 2016-12-31 | $-1.10 |
| 2016-09-30 | $-0.50 |
| 2016-06-30 | $-0.50 |
| 2016-03-31 | $-0.20 |
| 2015-12-31 | $0.00 |
| 2015-09-30 | $-0.50 |
| 2015-06-30 | $-0.30 |
| 2015-03-31 | $0.10 |
| 2014-12-31 | $1.00 |
| 2014-09-30 | $0.00 |
| 2014-06-30 | $-0.10 |
| 2014-03-31 | $0.00 |
| 2013-12-31 | $-0.08 |
| 2013-09-30 | $-0.02 |
| 2013-06-30 | $-0.10 |
| 2013-03-31 | $-0.10 |
| 2012-12-31 | $-0.30 |
| 2012-09-30 | $-0.40 |
| 2012-06-30 | $-0.10 |
| 2012-03-31 | $-0.20 |
| 2011-12-31 | $-0.20 |
| 2011-09-30 | $-0.10 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.000B | $0.000B |
| Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |